Cusabio Polyclonal Antibodies
REL Antibody | CSB-PA019552KA01HU
- SKU:
- CSB-PA019552KA01HU
- Availability:
- 3 to 7 Working Days
- Size:
- 100ul (100ug)
Description
REL Antibody | CSB-PA019552KA01HU | Cusabio
REL Antibody is Available at Gentaur Genprice with the fastest delivery.
Online Order Payment is possible or send quotation to info@gentaur.com.
Product Type: Polyclonal Antibody
Target Names: REL
Aliases: C-Rel; REL
Background: Transcription factors of the nuclear factor κ B (NF-κB) /Rel family play a pivotal role in inflammatory and immune responses. There are five family members in mammals: RelA, c-Rel, RelB, NF-κB1 (p105/p50), and NF-κB2 (p100/p52) . Both p105 and p100 are proteolytically processed by the proteasome to produce p50 and p52, respectively. Rel proteins bind p50 and p52 to form dimeric complexes that bind DNA and regulate transcription. In unstimulated cells, NF-κB is sequestered in the cytoplasm by IκB inhibitory proteins. NF-κB-activating agents can induce the phosphorylation of IκB proteins, targeting them for rapid degradation through the ubiquitin-proteasome pathway and releasing NF-κB to enter the nucleus where it regulates gene expression. NIK and IKKα (IKK1) regulate the phosphorylation and processing of NF-κB2 (p100) to produce p52, which translocates to the nucleus.
Isotype: IgG
Conjugate: Non-conjugated
Clonality: Polyclonal
Uniport ID: Q04864
Host Species: Rabbit
Species Reactivity: Human, Mouse, Rat
Immunogen: Recombinant protein of human REL
Immunogen Species: Human
Applications: ELISA, WB, IHC
Tested Applications: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Purification Method: Affinity purification
Dilution Ratio1: ELISA:1:2000-1:10000
Dilution Ratio2: WB:1:500-1:2000
Dilution Ratio3: IHC:1:50-1:200
Dilution Ratio4:
Dilution Ratio5:
Dilution Ratio6:
Buffer: Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form: liquid
Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Initial Research Areas: Signal Transduction
Research Areas: Epigenetics & Nuclear Signaling;Cancer;Signal transduction